

Jason M Uslaner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679479/publications.pdf>

Version: 2024-02-01

54
papers

2,105
citations

172457

29
h-index

233421

45
g-index

54
all docs

54
docs citations

54
times ranked

2412
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. <i>Neuropharmacology</i> , 2009, 57, 531-538.	4.1	170
2	The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. <i>Behavioural Brain Research</i> , 2006, 169, 320-324.	2.2	152
3	Subthalamic nucleus lesions increase impulsive action and decrease impulsive choice—mediation by enhanced incentive motivation?. <i>European Journal of Neuroscience</i> , 2006, 24, 2345-2354.	2.6	114
4	Amphetamine and cocaine induce different patterns of c-fos mRNA expression in the striatum and subthalamic nucleus depending on environmental context. <i>European Journal of Neuroscience</i> , 2001, 13, 1977-1983.	2.6	105
5	The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4 <i>H</i> -Thieno [3,2- <i>b</i>]pyrrole-5-carboxylic Acid] and d-Serine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 921-930.	2.5	80
6	The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. <i>BMC Neuroscience</i> , 2013, 14, 90.	1.9	79
7	Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition. <i>Science Translational Medicine</i> , 2013, 5, 179ra44.	12.4	79
8	The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. <i>Neuropharmacology</i> , 2013, 64, 215-223.	4.1	77
9	Mechanism based neurotoxicity of mGlu5 positive allosteric modulators—Development challenges for a promising novel antipsychotic target. <i>Neuropharmacology</i> , 2014, 82, 161-173.	4.1	76
10	MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 223-229.	2.9	68
11	The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. <i>Psychopharmacology</i> , 2013, 225, 21-30.	3.1	63
12	The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 442-450.	2.5	62
13	Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. <i>Neuropharmacology</i> , 2012, 62, 1453-1460.	4.1	58
14	The Influence of Subthalamic Nucleus Lesions on Sign-Tracking to Stimuli Paired with Food and Drug Rewards: Facilitation of Incentive Salience Attribution?. <i>Neuropsychopharmacology</i> , 2008, 33, 2352-2361.	5.4	55
15	The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 101, 35-40.	2.9	52
16	Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7888-7894.	6.4	48
17	Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. <i>Psychopharmacology</i> , 2015, 232, 1859-1866.	3.1	48
18	Amphetamine-induced c-fos mRNA expression in the caudate putamen and subthalamic nucleus: interactions between dose, environment, and neuronal phenotype. <i>Journal of Neurochemistry</i> , 2003, 85, 105-114.	3.9	39

#	ARTICLE	IF	CITATIONS
19	The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. <i>Behavioural Brain Research</i> , 2015, 287, 96-99.	2.2	39
20	Differential sleep-promoting effects of dual orexin receptor antagonists and GABA receptor modulators. <i>BMC Neuroscience</i> , 2014, 15, 109.	1.9	37
21	Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 92-106.	3.1	37
22	Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement. <i>Behavioural Brain Research</i> , 2014, 269, 61-65.	2.2	36
23	Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. <i>Sleep</i> , 2016, 39, 603-612.	1.1	35
24	Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 182.	2.0	34
25	Cocaine-induced psychomotor activity is associated with its ability to induce c-fos mRNA expression in the subthalamic nucleus: effects of dose and repeated treatment. <i>European Journal of Neuroscience</i> , 2003, 17, 2180-2186.	2.6	32
26	Subthalamic Nucleus Lesions Enhance the Psychomotor-Activating, Incentive Motivational, and Neurobiological Effects of Cocaine. <i>Journal of Neuroscience</i> , 2005, 25, 8407-8415.	3.6	32
27	Preclinical to Human Translational Pharmacology of the Novel M ₁ Positive Allosteric Modulator MK-7622. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 556-566.	2.5	32
28	T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. <i>Neuropharmacology</i> , 2012, 62, 1413-1421.	4.1	31
29	Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5903-5908.	2.2	31
30	Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. <i>Frontiers in Neuroscience</i> , 2013, 7, 254.	2.8	30
31	Discovery of [¹¹ C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M ₄ Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2411-2425.	6.4	30
32	Combined administration of an mGlu2/3 receptor agonist and a 5-HT _{2A} receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. <i>Psychopharmacology</i> , 2009, 206, 641-651.	3.1	29
33	The nicotinic $\alpha 7$ receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. <i>Neuropharmacology</i> , 2013, 64, 191-196.	4.1	28
34	The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. <i>Psychopharmacology</i> , 2014, 231, 511-519.	3.1	27
35	Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 126-132.	2.2	18
36	The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. <i>Neuropharmacology</i> , 2015, 99, 256-263.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M ₄ Positive Allosteric Modulators. <i>ChemMedChem</i> , 2019, 14, 943-951.	3.2	16
38	T-Type Calcium Channel Antagonism Decreases Motivation for Nicotine and Blocks Nicotine- and Cue-Induced Reinstatement for a Response Previously Reinforced with Nicotine. <i>Biological Psychiatry</i> , 2010, 68, 712-718.	1.3	15
39	Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose. <i>Behavioural Brain Research</i> , 2010, 207, 37-43.	2.2	10
40	The PET tracer [¹¹ C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. <i>Science Translational Medicine</i> , 2022, 14, eab3684.	12.4	10
41	Pharmacological validation of a novel nonhuman primate measure of thermal responsivity with utility for predicting analgesic effects. <i>Journal of Pain Research</i> , 2018, Volume 11, 735-741.	2.0	9
42	Pharmacological Characterization of the Novel and Selective $\alpha 7$ Nicotinic Acetylcholine Receptor Positive Allosteric Modulator BNC375. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 311-324.	2.5	9
43	Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 312-317.	2.8	8
44	Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1260-1264.	2.2	8
45	Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 815-820.	2.8	8
46	The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. <i>Journal of Neurochemistry</i> , 2017, 142, 204-214.	3.9	7
47	The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 161-168.	4.9	7
48	Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey. <i>Neuropharmacology</i> , 2021, 197, 108754.	4.1	6
49	Activators of $\alpha 7$ nAChR as Potential Therapeutics for Cognitive Impairment. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 45, 209-245.	1.7	4
50	Discovery of 4-arylquinoline-2-carboxamides, highly potent and selective class of mGluR2 negative allosteric modulators: From HTS to activity in animal models. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127066.	2.2	3
51	Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. <i>Psychopharmacology</i> , 2016, 233, 2441-2450.	3.1	2
52	A New Class of Hypnotic Compounds for the Treatment of Insomnia: The Dual Orexin Receptor Antagonists. , 2015, , 323-338.		2
53	Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1122-1126.	2.2	1
54	A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized 1H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an $\alpha 7$ Nicotinic Acetylcholine Receptor Positive Allosteric Modulator. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, , .	1.5	0